GRAYMEDY

02 / MEDICINES & EVERYDAY LIFE

PHASE 2 / COMPANY TOPLINE

A phase 2 coeliac disease announcement points to intestinal protection. A future medicine must

also prove that it makes daily life better.

The burden behind the label

The size of the benefit matters

A meal can be a calculation: the ingredients, the

A p-value does not measure how much a treatment

preparation surface, the shared serving spoon. For

helps. The absolute difference between groups, the

people managing coeliac disease, avoiding gluten is a

uncertainty around that estimate and the number of

medical necessity that reaches into ordinary social life.

people who stop treatment all affect the clinical picture.

That is the context in which a potential medicine should

Tissue protection, symptom relief and durable benefit

be judged. A laboratory or biopsy result matters, but so

are separate outcomes. A statistically significant biopsy

does whether a treatment could eventually make an

result can support further development while leaving its

accidental exposure less consequential. October's

everyday importance uncertain. Detailed efficacy and

FB102 news brings that possibility closer to a serious

safety results are needed to establish how much

test without establishing that it has been achieved.

protection FB102 provides, how consistently it works

and whether its benefits justify the risks and

The October result

inconvenience of treatment.

On 8 October, argenx announced that its

The care people need today

investigational anti-CD122 antibody, FB102, met the

primary endpoint in a phase 2 trial. The study enrolled

NIDDK describes a gluten-free diet as the central

126 adults and compared two intravenous dose levels

treatment for coeliac disease. Gluten triggers an

with placebo during a controlled eight-week gluten

immune reaction that damages the small intestine.

challenge. The endpoint assessed change in the ratio

Specialist dietetic support can help people read labels,

of villus height to crypt depth at day 78, a measure of

plan meals and maintain nutritional balance. Follow-up

intestinal architecture. The company reported p=0.0176

may include blood tests and, in some cases, further

and plans phase 3 development. Detailed results were

biopsies to assess healing. Continuing symptoms

still to be presented. [6]

deserve investigation rather than an assumption that

the diet has simply failed; exposure and other

conditions can contribute. [7]

04

HEALTH SCIENCE, CLEARLY